An oncolytic virus is a unique virus that favorably infects and kills cancer cells. These are deployed as a part of cancer immunotherapy and act by selectively targeting cancer cells and carrying out oncolysis. The oncolytic virus is known to kill the cancer cells directly and stimulate the patient's own anti-tumor immune responses. The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of skin melanoma. Inevitable changes in the environment occurring due to human activity are giving rise to various factors leading to an increase in the incidence of numerous cutaneous malignancies, including non-melanoma skin cancer. The conventional radiation and chemotherapy for the treatment of various cancers, including skin melanomas, have a restricted therapeutic index and an array of therapy related side effects. The first US FDA approved oncolytic herpes virus (a modified herpes simplex virus) is the drug talimogene laherparepvec (OncoVex, T-VEC), approved in 2015 for the treatment of advanced inoperable melanoma.
MARKET DYNAMICS
The increasing incidence rate of cancers and rise in adoption of advanced treatment options will spur the demand of the oncolytic virus market. However, treatment-related off-target effects, side effects, and drug resistance may restraint the growth of the market in the forecasted period. Additionally, huge investment in research and development and rising geriatric population and changing lifestyle in developing economies will boost the growth of the market in the forecasted period.
MARKET SCOPE
The "Global Oncolytic Virus Market Analysis to 2028" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncolytic virus market with detailed market segmentation by product type, application, end-users, and geography. The global oncolytic virus market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading oncolytic virus market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global oncolytic virus market is segmented on the product type, application and end-users. Based on product type, the global oncolytic virus market is segmented into HSV-based oncolytic viruses, Adenoviruses-based oncolytic viruses, Vaccinia virus-based oncolytic viruses, Vesicular Stomatitis virus-based oncolytic viruses, and Newcastle disease virus-based oncolytic viruses. Based on application, the global oncolytic virus market is segmented into breast cancer, lung cancer, prostate cancer, melanoma, brain tumor, blood cancer, and others. Based on the end-users, the oncolytic virus market is segmented hospitals, specialty clinics, and cancer research institutes.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global oncolytic virus market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The oncolytic virus market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting oncolytic virus market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the oncolytic virus market in these regions.
MARKET PLAYERS
The reports cover key developments in the oncolytic virus market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from oncolytic virus market are anticipated to lucrative growth opportunities in the future with the rising demand for oncolytic virus in the global market. Below mentioned is the list of few companies engaged in the oncolytic virus market.
The report also includes the profiles of key oncolytic virus market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Amgen Inc
- Oncolytics Biotech, Inc.
- Merck & Co., Inc.
- Transgene
- Oncolys BioPharma Inc.
- Targovax ASA
- Vyriad Inc.
- Genelux Corporation
- Sorrento Therapeutics, Inc.
- Lokon Pharma AB
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.